成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. 誘導(dǎo)疾病模型產(chǎn)品 Immunology/Inflammation Vitamin D Related/Nuclear Receptor Autophagy Anti-infection Antibody-drug Conjugate/ADC Related
  3. 內(nèi)分泌與代謝疾病模型 神經(jīng)系統(tǒng)疾病模型 心血管系統(tǒng)疾病模型 Glucocorticoid Receptor SARS-CoV Autophagy Complement System Mitophagy Bacterial Antibiotic ADC Cytotoxin
  4. 肌肉萎縮模型 抑郁癥模型 高血壓模型
  5. Dexamethasone

Dexamethasone  (Synonyms: 地塞米松; Hexadecadrol; Prednisolone F)

目錄號: HY-14648 純度: 99.86%
COA 產(chǎn)品使用指南

Dexamethasone (Hexadecadrol) 是糖皮質(zhì)激素受體 (glucocorticoid receptor) 激動(dòng)劑、凋亡誘導(dǎo)劑，和常見的實(shí)驗(yàn)動(dòng)物的疾病誘導(dǎo)劑，可構(gòu)建肌肉萎縮、高血壓和抑郁模型。Dexamethasone 可抑制巨噬細(xì)胞中炎性 miRNA-155 外泌體的產(chǎn)生，顯著降低中性粒細(xì)胞以及單核細(xì)胞的炎癥因子表達(dá)。Dexamethasone 還有潛力用于 COVID-19 的研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Dexamethasone Chemical Structure

Dexamethasone Chemical Structure

CAS No. : 50-02-2

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
100 mg ￥350
In-stock
500 mg ￥500
In-stock
1 g ￥837
In-stock
5 g ￥2046
In-stock
10 g   詢價(jià)  
50 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 164 篇科研文獻(xiàn)

WB
IF
Proliferation Assay
RT-PCR

    Dexamethasone purchased from MCE. Usage Cited in: Carbohydr Polym. 1 January 2023, 120179.

    Western blotting analysis of Itgb2 levels in Dexamethasone (100 nM; for 1 hour)-treated MODE-K cells.

    Dexamethasone purchased from MCE. Usage Cited in: Carbohydr Polym. 1 January 2023, 120179.

    mRNA levels of Itgb2 in Dexamethasone (100 nM; for 1 hour)-treated MODE-K cells.

    Dexamethasone purchased from MCE. Usage Cited in: Carbohydr Polym. 1 January 2023, 120179.

    Immunofluorescence analysis of Itgb2 in Dexamethasone (100 nM; for 1 hour)-treated MODE-K cells.

    Dexamethasone purchased from MCE. Usage Cited in: J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2017-2030.  [Abstract]

    qRT‐PCR results show that DEX (DEX; 25 μg/g ; once a day; for 10 days)-induced myotube atrophy can increase the expression levels of MuRF1, Atrogin‐1, FoxO3a, SYISL, and miR‐205‐5p, decrease the expression levels of miR‐23a‐3p and miR‐103‐3p, but does not affect the expression level of SYNPO2.

    Dexamethasone purchased from MCE. Usage Cited in: J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2017-2030.  [Abstract]

    Representative photographs of H&E and Lamin immunofluorescence staining for WT and KO TA muscles. Quantification of five independent experiments shows that knockout of SYISL alleviates muscle weight loss caused by Dexamethasone (DEX; 25 μg/g ; once a day; for 10 days)-induced muscle atrophy.

    Dexamethasone purchased from MCE. Usage Cited in: J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2017-2030.  [Abstract]

    Western blotting results show that SYISL overexpression can further promote protein ubiquitination levels in Dexamethasone (DEX; 25 μg/g ; once a day; for 10 days)-induced muscular atrophy. Muscle atrophy is induced by intraperitoneal injection of DEX for 10 days in 3‐month‐old wild‐type and KO mice, respectively.

    Dexamethasone purchased from MCE. Usage Cited in: Br J Pharmacol. 2021 Aug;178(15):2976-2997.  [Abstract]

    Primary microglial cells incubated with Protopanaxadiol (100 μM), Dexamethasone (100 nM) or Dexamethasone-BSA (10 nM) show remarkable dynorphin A expression. Pretreatment with Dexamethasone-21-mesylate for 0.5 h completely abolished Protopanaxadiol-, Dexamethasone- or Dexamethasone-BSA-stimulated dynorphin A expression.

    Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378.  [Abstract]

    The migration assay of 4T1 cells in different condition. 4T1 cells were pretreated with 100?nM Dexamethasone (Dex) for 48?h and then are used for Transwell.

    Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378.  [Abstract]

    4T1 cells are treated with Dexamethasone (Dex; 100 nM)/GSK650394 in vitro for 48?h before inoculation via intravenous injection.

    Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378.  [Abstract]

    The GR expression of 4T1 cells treated with Dexamethasone (100 nM)/Mifepristone for 48?h.

    Dexamethasone purchased from MCE. Usage Cited in: Oncogene. 2021 Sep;40(35):5367-5378.  [Abstract]

    For in situ treatment in the 4T1 tumor model, Dexamethasone (Dex; 3?mg/kg) is performed every three days by gavage twice/day. The expression of Nedd4l, p-Nedd4l, Smad2 and p-Smad2 after SGK1 knockout.

    Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730.  [Abstract]

    Western blot analysis of iRhom2, TNF-α, and BAFF expression in Raw264.7 cells treated with various concentrations of blank NPs, free Dexamethasone (Dex), Dex/Oxi-αCD NPs, or Dex/FA-Oxi-αCD NPs for 24 h.

    Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730.  [Abstract]

    Raw264.7 cells are treated with various concentrations of blank NPs, free Dexamethasone (Dex), Dex/Oxi-αCD NPs, or Dex/FA-Oxi-αCD NPs for 24 h, mRNA level of iRhom2 in Raw264.7 cells is detected by quantitative real-time PCR. Data are presented by the relative amount of mRNA normalized by GAPDH.

    Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730.  [Abstract]

    Raw264.7 cells are treated with various concentrations of blank NPs, free Dexamethasone (Dex), Dex/Oxi-αCD NPs, or Dex/FA-Oxi-αCD NPs for 24 h, the optical density values at 450 nm were measured and the cell viability was determined by CCK-8 assay.

    Dexamethasone purchased from MCE. Usage Cited in: Biomaterials. 2020 Feb;232:119730.  [Abstract]

    Raw264.7 macrophages induced with LPS (1 μg/mL) for 6 h. Then cellular uptake of Cy5-labeled Dexamethasone (Dex)/OxiαCD NPs or Dex/FA-Oxi-αCD NPs is assessed using confocal laser scanning microscopy at various times.

    Dexamethasone purchased from MCE. Usage Cited in: Biochem Pharmacol. 2020 Oct;180:114145.  [Abstract]

    Translocation of FoxO3 after treatment with S-Rg3 in DEX-treated C2C12 myotubes was investigated by immunofluorescence staining.

    Dexamethasone purchased from MCE. Usage Cited in: Biochem Pharmacol. 2020 Oct;180:114145.  [Abstract]

    After C2C12 myotubes are incubated with Dexamethasone (DEX) and S-Rg3 for 24 h, myotube levels of MuRF1 and atrogin-1 are detected using Western blot analysis.

    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist, apoptosis inducer, and common disease inducer in experimental animals, constructing models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has potential for use in COVID-19 research[1][2][3][4].

    IC50 & Target

    Glucocorticoid receptor[1]
    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    > 15 μM
    Compound: Dex
    Anticancer against human A549 cells after 72 hrs by MTT assay
    Anticancer against human A549 cells after 72 hrs by MTT assay
    		[PMID: 24992071]
    A549 EC50
    1 nM
    Compound: Dexamethasone
    Activity at glucocorticoid receptor in human A549 cells assessed as effect on GRE promoter response by luciferase reporter assay
    Activity at glucocorticoid receptor in human A549 cells assessed as effect on GRE promoter response by luciferase reporter assay
    		[PMID: 16643060]
    A549 EC50
    1.1 nM
    Compound: Dexamethasone
    Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of IL-1-beta-induced NF-kappaB dependent E-selection promoter activation after 6 hrs by luciferase reporter gene based ELAM assay
    Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of IL-1-beta-induced NF-kappaB dependent E-selection promoter activation after 6 hrs by luciferase reporter gene based ELAM assay
    		[PMID: 20047280]
    A549 EC50
    1.1 nM
    Compound: 1, Dex
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as E-selectin transrepression by luciferase reporter gene assay
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as E-selectin transrepression by luciferase reporter gene assay
    		[PMID: 24980053]
    A549 EC50
    1.1 nM
    Compound: 1, Dex
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL-1beta-induced NF-kappaB dependent E-selectin activation by luciferase reporter gene assay
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL-1beta-induced NF-kappaB dependent E-selectin activation by luciferase reporter gene assay
    		[PMID: 23953070]
    A549 EC50
    1.1 nM
    Compound: Dex
    Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay
    Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay
    		[PMID: 23916594]
    A549 EC50
    1.1 nM
    Compound: 1, dex
    Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay
    Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay
    		[PMID: 21073190]
    A549 EC50
    1.1 nM
    Compound: dex
    Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay
    Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay
    		[PMID: 19321341]
    A549 EC50
    2.5 nM
    Compound: Dexamethasone
    Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of PMA-induced AP1 activity after 6 hrs by luciferase reporter gene assay
    Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of PMA-induced AP1 activity after 6 hrs by luciferase reporter gene assay
    		[PMID: 20047280]
    A549 EC50
    2.5 nM
    Compound: 1, Dex
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as AP-1 transrepression by luciferase reporter gene assay
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as AP-1 transrepression by luciferase reporter gene assay
    		[PMID: 24980053]
    A549 EC50
    2.5 nM
    Compound: Dexamethasone
    Transrepression of glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay
    Transrepression of glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay
    		[PMID: 24011644]
    A549 EC50
    2.5 nM
    Compound: 1, Dex
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activation by luciferase reporter gene assay
    Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activation by luciferase reporter gene assay
    		[PMID: 23953070]
    A549 EC50
    2.5 nM
    Compound: Dex
    Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-stimulated AP1 response element by luciferase reporter gene assay
    Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-stimulated AP1 response element by luciferase reporter gene assay
    		[PMID: 23916594]
    A549 EC50
    2.5 nM
    Compound: 1, dex
    Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay
    Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay
    		[PMID: 21073190]
    B16-F10 IC50
    > 20 μM
    Compound: Dex
    Anticancer against mouse B16F10 cells after 72 hrs by MTT assay
    Anticancer against mouse B16F10 cells after 72 hrs by MTT assay
    		[PMID: 24992071]
    B-cell IC50
    0.8 μM
    Compound: Dexamethasone
    Immunosuppressive activity against BALB/C mouse B lymphocytes assessed as reduction in LPS-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method
    Immunosuppressive activity against BALB/C mouse B lymphocytes assessed as reduction in LPS-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method
    		[PMID: 31961677]
    BV-2 IC50
    2.5 x 10-2 μM
    Compound: Dexamethasone
    Antiinflammatory activity in C57BL6/J mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
    Antiinflammatory activity in C57BL6/J mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
    		[PMID: 26110443]
    CHO IC50
    > 20 μM
    Compound: Dex
    Cytotoxicity against CHO cells after 72 hrs by MTT assay
    Cytotoxicity against CHO cells after 72 hrs by MTT assay
    		[PMID: 24992071]
    COS-7 EC50
    7.2 nM
    Compound: Dexamethasone
    Agonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay
    Agonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay
    		[PMID: 19863083]
    CV-1 ED50
    0.1 nM
    Compound: dexamethasone
    Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay
    Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay
    		[PMID: 18032610]
    CV-1 EC50
    0.2 nM
    Compound: dexamethasone
    Agonist activity at human GR expressed in CV1 cells by GRE activation assay
    Agonist activity at human GR expressed in CV1 cells by GRE activation assay
    		[PMID: 17705362]
    Fibroblast IC50
    > 15 μM
    Compound: Dex
    Cytotoxicity against mouse fibroblasts after 72 hrs by MTT assay
    Cytotoxicity against mouse fibroblasts after 72 hrs by MTT assay
    		[PMID: 24992071]
    HEK293 IC50
    > 500 μM
    Compound: dexamethasone
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    		[PMID: 23241029]
    HEK293 EC50
    1.3 nM
    Compound: DEX
    Agonist activity at human GCR expressed in HEK293 cells by luciferase reporter gene assay
    Agonist activity at human GCR expressed in HEK293 cells by luciferase reporter gene assay
    		[PMID: 25305688]
    HEK-293T IC50
    > 20 μM
    Compound: Dex
    Cytotoxicity against HEK293T cells after 72 hrs by MTT assay
    Cytotoxicity against HEK293T cells after 72 hrs by MTT assay
    		[PMID: 24992071]
    HeLa EC50
    17 nM
    Compound: 1a
    Activation of MMTV in HeLa cells measured by luciferase activity
    Activation of MMTV in HeLa cells measured by luciferase activity
    		[PMID: 17181172]
    HeLa EC50
    17 nM
    Compound: Dexamethasone
    Transactivation of glucocorticoid receptor in human HeLa cells harboring MMTV promoter by luciferase reporter gene assay
    Transactivation of glucocorticoid receptor in human HeLa cells harboring MMTV promoter by luciferase reporter gene assay
    		[PMID: 24656565]
    HeLa EC50
    4.2 nM
    Compound: Dexamethasone
    Transactivation of GR-LBD expressed in human HeLa cells co-expressing GAL4-DBD by luciferase reporter gene assay
    Transactivation of GR-LBD expressed in human HeLa cells co-expressing GAL4-DBD by luciferase reporter gene assay
    		[PMID: 24011644]
    HeLa EC50
    4.2 nM
    Compound: 1, dex
    Transactivation activity of glucocorticoid receptor ligand binding domain expressed in human NP-1 Hela cells co-expressing GAL4 DNA binding domain by luciferase reporter gene assay
    Transactivation activity of glucocorticoid receptor ligand binding domain expressed in human NP-1 Hela cells co-expressing GAL4 DNA binding domain by luciferase reporter gene assay
    		[PMID: 21073190]
    HeLa EC50
    4.5 nM
    Compound: 1, Dex
    Agonist activity at glucocorticoid receptor in human HeLa cells assessed as NP-1 transactivation by luciferase reporter gene assay
    Agonist activity at glucocorticoid receptor in human HeLa cells assessed as NP-1 transactivation by luciferase reporter gene assay
    		[PMID: 24980053]
    HeLa EC50
    4.5 nM
    Compound: 1, Dex
    Transactivation of glucocorticoid receptor ligand binding domain (unknown origin) transfected in human HeLa cells assessed as activation of NP-1 by GAL4 luciferase reporter gene assay
    Transactivation of glucocorticoid receptor ligand binding domain (unknown origin) transfected in human HeLa cells assessed as activation of NP-1 by GAL4 luciferase reporter gene assay
    		[PMID: 23953070]
    HeLa EC50
    4.5 nM
    Compound: Dex
    Transactivation activity at glucocorticoid receptor ligand binding domain (unknown origin) expressed in human Hela cells co-expressing GAL4 DNA binding domain assessed as NP-1-stimulated GRE activation by luciferase reporter gene assay
    Transactivation activity at glucocorticoid receptor ligand binding domain (unknown origin) expressed in human Hela cells co-expressing GAL4 DNA binding domain assessed as NP-1-stimulated GRE activation by luciferase reporter gene assay
    		[PMID: 23916594]
    HeLa EC50
    4.5 nM
    Compound: Dexamethasone
    Transactivation of GAL-4 tagged glucocorticoid receptor ligand binding domain expressed in human HeLa cells assessed as NP1 activation by luciferase reporter gene assay
    Transactivation of GAL-4 tagged glucocorticoid receptor ligand binding domain expressed in human HeLa cells assessed as NP1 activation by luciferase reporter gene assay
    		[PMID: 20047280]
    HeLa S3 IC50
    4.1 nM
    Compound: dexamethasone
    Displacement of [3H]Dexamethasone from glucocorticoid receptor in human HeLaS3 cells after 2 hrs
    Displacement of [3H]Dexamethasone from glucocorticoid receptor in human HeLaS3 cells after 2 hrs
    		[PMID: 23403082]
    HepG2 EC50
    2.6 μM
    Compound: Dexamethasone
    Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
    Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
    		[PMID: 20966043]
    HFF EC50
    0.5 nM
    Compound: dexamethasone
    Antiinflammatory activity assessed as inhibition of IL1 stimulated IL6 production in HFF cells by transrepression assay
    Antiinflammatory activity assessed as inhibition of IL1 stimulated IL6 production in HFF cells by transrepression assay
    		[PMID: 17692519]
    HFF EC50
    1.9 nM
    Compound: 1a
    Induction of aromatase activity in HFF cells assessed as production of beta estradiol by aromatase assay
    Induction of aromatase activity in HFF cells assessed as production of beta estradiol by aromatase assay
    		[PMID: 17181172]
    HFF EC50
    2 nM
    Compound: dexamethasone
    Antiinflammatory activity assessed as upregulation of aromatase in HFF cells by transactivation assay
    Antiinflammatory activity assessed as upregulation of aromatase in HFF cells by transactivation assay
    		[PMID: 17692519]
    Huh-7 EC50
    5 nM
    Compound: 1, dex
    Transactivation activity at glucocorticoid receptor in human 13D3/Huh7 cells assessed as induction of tyrosine aminotransferase activity after 24 hrs
    Transactivation activity at glucocorticoid receptor in human 13D3/Huh7 cells assessed as induction of tyrosine aminotransferase activity after 24 hrs
    		[PMID: 21073190]
    J774 IC50
    5.2 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS/IFNgamma-induced NO production incubated for 24 hrs by Griess method
    Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS/IFNgamma-induced NO production incubated for 24 hrs by Griess method
    		[PMID: 32364737]
    J774 CC50
    91.1 μM
    Compound: Dexa
    Cytotoxicity against BALB/c mouse J774 cells assessed as reduction in cell viability after 72 hrs by alamarBlue assay
    Cytotoxicity against BALB/c mouse J774 cells assessed as reduction in cell viability after 72 hrs by alamarBlue assay
    		[PMID: 29523468]
    J774.1 IC50
    170 μM
    Compound: dexamethasone
    Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs
    Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs
    		[PMID: 12608860]
    J774.A1 IC50
    0.165 μg/mL
    Compound: Dexamethasone
    Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    		[PMID: 25113933]
    J774.A1 IC50
    0.4 μM
    Compound: DEXA
    Inhibition of TNFalpha production in mouse J774A.1 cells incubated for 6 hrs by sandwich immunoassay
    Inhibition of TNFalpha production in mouse J774A.1 cells incubated for 6 hrs by sandwich immunoassay
    		[PMID: 25824662]
    J774.A1 IC50
    22 μM
    Compound: DEXA
    Inhibition of IL-1beta production in mouse J774A.1 cells incubated for 12 hrs by sandwich immunoassay
    Inhibition of IL-1beta production in mouse J774A.1 cells incubated for 12 hrs by sandwich immunoassay
    		[PMID: 25824662]
    J774.A1 IC50
    9.09 μg/mL
    Compound: Dexamethasone
    Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    		[PMID: 25113933]
    L02 IC50
    4620.58 μM
    Compound: Dex
    Antiinflammatory activity against human L02 assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess assay relative to control
    Antiinflammatory activity against human L02 assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess assay relative to control
    		[PMID: 33515864]
    L02 IC50
    4620.58 μM
    Compound: Dex
    Cytotoxicity against human L02 cells cells assessed as cell viability by MTT assay
    Cytotoxicity against human L02 cells cells assessed as cell viability by MTT assay
    		[PMID: 33515864]
    LLC-PK1 IC50
    > 50 μM
    Compound: Dexamethasone
    Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
    Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
    		[PMID: 12699389]
    LLC-PK1 IC50
    > 50 μM
    Compound: Dexamethasone
    Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
    Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
    		[PMID: 12699389]
    LLC-PK1 IC50
    > 50 μM
    Compound: Dexamethasone
    Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
    Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
    		[PMID: 12699389]
    Macrophage IC50
    0.134 μM
    Compound: Dexamethasone
    Inhibition of TNFalpha expression in LPS-induced macrophages (unknown origin) incubated for 24 hrs by ELISA
    Inhibition of TNFalpha expression in LPS-induced macrophages (unknown origin) incubated for 24 hrs by ELISA
    		[PMID: 31473042]
    MCF7 IC50
    > 15 μM
    Compound: Dex
    Anticancer against human MCF7 cells after 72 hrs by MTT assay
    Anticancer against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 24992071]
    Multiple myeloma cancer stem cell IC50
    > 100000 nM
    Compound: DEX
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    		[PMID: 30108696]
    PBMC EC50
    > 0.2 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MCP-1 production after 24 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MCP-1 production after 24 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.00047 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced GM-CSF production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced GM-CSF production after 48 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.00092 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-4 production after 24 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-4 production after 24 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.001 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-5 production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-5 production after 48 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0012 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-13 production after 24 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-13 production after 24 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0019 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced TNFalpha production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced TNFalpha production after 48 hrs
    		[PMID: 23199485]
    PBMC IC50
    0.002 μM
    Compound: dexamethasone
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry
    		[PMID: 25338180]
    PBMC EC50
    0.0021 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-1beta production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-1beta production after 48 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0024 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IP-10 production after 24 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IP-10 production after 24 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0035 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-3 production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-3 production after 48 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0036 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-2 production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-2 production after 48 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0041 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-12p70 production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-12p70 production after 48 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0055 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-10 production after 48 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-10 production after 48 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0061 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced TNFalpha production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced TNFalpha production after 6 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.0076 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IFNgamma production after 24 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IFNgamma production after 24 hrs
    		[PMID: 23199485]
    PBMC IC50
    0.008 μM
    Compound: dexamethasone
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry
    		[PMID: 25338180]
    PBMC IC50
    0.009 μM
    Compound: dexamethasone
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry
    		[PMID: 25338180]
    PBMC EC50
    0.0094 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-1beta production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-1beta production after 6 hrs
    		[PMID: 23199485]
    PBMC IC50
    0.0095 μM
    Compound: Dexamethasone
    Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay
    Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay
    		[PMID: 23411072]
    PBMC EC50
    0.01 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 6 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.014 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta production after 6 hrs
    		[PMID: 23199485]
    PBMC IC50
    0.017 μM
    Compound: Dexamethasone
    Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay
    Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay
    		[PMID: 23411072]
    PBMC EC50
    0.055 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 production after 6 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.066 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced MIP1alpha production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced MIP1alpha production after 6 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.072 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 production after 6 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.082 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-6 production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-6 production after 6 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.088 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-8 production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-8 production after 6 hrs
    		[PMID: 23199485]
    PBMC EC50
    0.13 μM
    Compound: 1
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MIP1alpha production after 6 hrs
    Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MIP1alpha production after 6 hrs
    		[PMID: 23199485]
    PBMC IC50
    3.6 nM
    Compound: Dexamethasone
    Inhibition of TNF-alpha production in LPS-stimulated human PBMC measured after 24 hrs by ELISA
    Inhibition of TNF-alpha production in LPS-stimulated human PBMC measured after 24 hrs by ELISA
    		[PMID: 35870364]
    Peritoneal macrophage IC50
    0.15 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse peritoneal macrophages assessed as inhibition of LPS-induced NO production incubated for 22 hrs by Griess reagent based colorimetric assay
    Anti-inflammatory activity in mouse peritoneal macrophages assessed as inhibition of LPS-induced NO production incubated for 22 hrs by Griess reagent based colorimetric assay
    		[PMID: 31358465]
    R1 IC50
    5 nM
    Compound: Dexamethasone
    Inhibition of glucocorticoid receptor-glucocorticoid complex transfected in rat R1 cells assessed as down-regulation of TPA-responsive element proinflammatory gene expression at 10 uM after 24 hrs by beta-galactosidase assay
    Inhibition of glucocorticoid receptor-glucocorticoid complex transfected in rat R1 cells assessed as down-regulation of TPA-responsive element proinflammatory gene expression at 10 uM after 24 hrs by beta-galactosidase assay
    		[PMID: 18412397]
    RAW IC50
    20 nM
    Compound: DXM
    Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs
    Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs
    		[PMID: 17367124]
    RAW264.7 IC50
    > 25 μg/mL
    Compound: Dexamethasone
    Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay
    Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay
    		[PMID: 15165136]
    RAW264.7 CC50
    > 50 μM
    Compound: Dexamethasone
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 30528697]
    RAW264.7 IC50
    > 50 μM
    Compound: Dex
    Cytotoxicity against LPS-induced mouse RAW 264.7 cells assessed as cell viability measured by MTT assay
    Cytotoxicity against LPS-induced mouse RAW 264.7 cells assessed as cell viability measured by MTT assay
    		[PMID: 33515864]
    RAW264.7 IC50
    > 50 μM
    Compound: Dex
    Cytotoxicity against mouse RAW 264.7 cells assessed as cell viability by MTT assay
    Cytotoxicity against mouse RAW 264.7 cells assessed as cell viability by MTT assay
    		[PMID: 33515864]
    RAW264.7 IC50
    0.01 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess assay
    		[PMID: 31301930]
    RAW264.7 IC50
    0.01 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS-stimulation and measured after 24 hrs by Griess assay
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS-stimulation and measured after 24 hrs by Griess assay
    		[PMID: 30931559]
    RAW264.7 IC50
    0.01 μM
    Compound: Dexsamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
    		[PMID: 21353543]
    RAW264.7 IC50
    0.016 μg/mL
    Compound: Dexamethasone
    Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    		[PMID: 25113933]
    RAW264.7 IC50
    0.04 μM
    Compound: DEXA
    Inhibition of TNFalpha production in mouse RAW264.7 cells incubated for 6 hrs by sandwich immunoassay
    Inhibition of TNFalpha production in mouse RAW264.7 cells incubated for 6 hrs by sandwich immunoassay
    		[PMID: 25824662]
    RAW264.7 IC50
    0.13 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay
    		[PMID: 30808589]
    RAW264.7 IC50
    0.47 μM
    Compound: Hexadecadrol
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method
    		[PMID: 22372956]
    RAW264.7 IC50
    0.58 μM
    Compound: Dex
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess reagent based assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess reagent based assay
    		[PMID: 34333975]
    RAW264.7 IC50
    0.62 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs
    		[PMID: 32485533]
    RAW264.7 IC50
    0.63 μM
    Compound: dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
    		[PMID: 26087384]
    RAW264.7 IC50
    0.63 μM
    Compound: DXM
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs in presence of LPS by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs in presence of LPS by Griess assay
    		[PMID: 27825545]
    RAW264.7 IC50
    0.7 μM
    Compound: dexamethasone
    Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as effect on TNFalpha formation pretreated 1 hr before LPS challenge measured after 24 hrs
    Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as effect on TNFalpha formation pretreated 1 hr before LPS challenge measured after 24 hrs
    		[PMID: 11908984]
    RAW264.7 IC50
    0.8 μM
    Compound: dexamethasone
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
    		[PMID: 26305406]
    RAW264.7 IC50
    0.8 μM
    Compound: Dexamethasone
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay relative to vehicle-treated control
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay relative to vehicle-treated control
    		[PMID: 25499882]
    RAW264.7 IC50
    0.8 μM
    Compound: Dexsamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    		[PMID: 21353543]
    RAW264.7 IC50
    0.8 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by griess assay
    		[PMID: 29272126]
    RAW264.7 IC50
    0.86 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 2 hrs before LPS challenge measured after 18 hrs by griess reaction
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 2 hrs before LPS challenge measured after 18 hrs by griess reaction
    		[PMID: 21288727]
    RAW264.7 IC50
    0.98 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method
    		[PMID: 22537362]
    RAW264.7 IC50
    1.2 μM
    Compound: DEX
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced TNF-alpha production after 48 hrs by ELISA
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced TNF-alpha production after 48 hrs by ELISA
    		[PMID: 30579802]
    RAW264.7 IC50
    1.43 μM
    Compound: dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method
    		[PMID: 23373965]
    RAW264.7 IC50
    1.84 μg/mL
    Compound: Dexamethasone
    Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay
    		[PMID: 25113933]
    RAW264.7 IC50
    10.7 μM
    Compound: Dexamethasone
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
    		[PMID: 29518326]
    RAW264.7 IC50
    14.75 μM
    Compound: Dexamethasone
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay
    		[PMID: 33933753]
    RAW264.7 IC50
    159.2 μM
    Compound: Dexamethasone
    Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by WST-1 assay
    Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by WST-1 assay
    		[PMID: 31260892]
    RAW264.7 IC50
    159.2 μM
    Compound: Dexamethasone
    Cytotoxicity against mouse RAW264.7 by WST-1 vital dye reagent method
    Cytotoxicity against mouse RAW264.7 by WST-1 vital dye reagent method
    		[PMID: 35567964]
    RAW264.7 IC50
    18.4 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 12 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 12 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay
    		[PMID: 31181925]
    RAW264.7 IC50
    2.5 μM
    Compound: Dexamethasone
    Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay
    Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay
    		[PMID: 28598633]
    RAW264.7 IC50
    2.66 μM
    Compound: Dex
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess assay
    		[PMID: 30108912]
    RAW264.7 IC50
    20 nM
    Compound: DXM
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction
    		[PMID: 21361338]
    RAW264.7 IC50
    22.2 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess reagent assay
    Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess reagent assay
    		[PMID: 35007071]
    RAW264.7 IC50
    24.3 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS addition and measured after 18 hrs by Griess reagent-based assay
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS addition and measured after 18 hrs by Griess reagent-based assay
    		[PMID: 32935986]
    RAW264.7 IC50
    32.5 μM
    Compound: DXMS
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
    		[PMID: 32070636]
    RAW264.7 IC50
    355.14 μM
    Compound: dexamethasone
    Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of PMA-induced macrophages respiratory burst measured up to 30 min by chemiluminescence method
    Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of PMA-induced macrophages respiratory burst measured up to 30 min by chemiluminescence method
    		10.1007/s00044-013-0504-9
    RAW264.7 IC50
    36 μg/mL
    Compound: Dexamethasone
    Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs
    Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs
    		[PMID: 15165136]
    RAW264.7 CC50
    4.4 μM
    Compound: Dexamethasone
    Cytotoxicity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue dye based colorimetric assay
    Cytotoxicity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue dye based colorimetric assay
    		[PMID: 35998343]
    RAW264.7 IC50
    4.7 μM
    Compound: DEXA
    Inhibition of IL-1beta production in mouse RAW264.7 cells incubated for 12 hrs by sandwich immunoassay
    Inhibition of IL-1beta production in mouse RAW264.7 cells incubated for 12 hrs by sandwich immunoassay
    		[PMID: 25824662]
    RAW264.7 IC50
    5.02 μM
    Compound: Dexamethasone
    Inhibition of NO release in mouse RAW264.7 incubated for 15 mins by fluoroscence-luminescence reader infinite M200 Pro analysis
    Inhibition of NO release in mouse RAW264.7 incubated for 15 mins by fluoroscence-luminescence reader infinite M200 Pro analysis
    		[PMID: 35567964]
    RAW264.7 IC50
    5.02 μM
    Compound: Dexamethasone
    Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO overproduction preincubated for 1 hr prior to Escherichia coli LPS stimulation followed by further incubation for 24 hrs by Griess reagent based spectrophotome
    Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO overproduction preincubated for 1 hr prior to Escherichia coli LPS stimulation followed by further incubation for 24 hrs by Griess reagent based spectrophotome
    		[PMID: 31260892]
    RAW264.7 IC50
    6 μM
    Compound: Dexamethasone
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent-based assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent-based assay
    		[PMID: 31577434]
    RAW264.7 IC50
    6.1 μM
    Compound: Dexamethasone
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 24 hrs by ELISA
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 24 hrs by ELISA
    		[PMID: 31577434]
    RAW264.7 IC50
    6.9 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs in presence of LPS by Griess reagent-based assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs in presence of LPS by Griess reagent-based assay
    		[PMID: 33914536]
    RAW264.7 IC50
    7 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
    		[PMID: 28499733]
    RAW264.7 IC50
    7.9 μM
    Compound: Dexamethasone
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
    		[PMID: 35063896]
    RAW264.7 IC50
    7.9 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess assay
    		[PMID: 30817151]
    RAW264.7 IC50
    7.9 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 3 hrs followed by LPS addition and measured after 24 hrs
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 3 hrs followed by LPS addition and measured after 24 hrs
    		[PMID: 37002536]
    RAW264.7 IC50
    8.28 μM
    Compound: Dexamethasone
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent-based assay
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent-based assay
    		[PMID: 33667092]
    RAW264.7 IC50
    8.4 μM
    Compound: Dexamethasone
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 secretion after 24 hrs by ELISA
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 secretion after 24 hrs by ELISA
    		[PMID: 31577434]
    RAW264.7 IC50
    8.7 μM
    Compound: Dexamethasone
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production pretreated for 30 mins followed by LPS stimulation for 24 hrs by ELISA
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production pretreated for 30 mins followed by LPS stimulation for 24 hrs by ELISA
    		[PMID: 30528697]
    RAW264.7 IC50
    8.71 μM
    Compound: Dex
    Inhibition of LPS-induced NO release in mouse RAW264.7 cells preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
    Inhibition of LPS-induced NO release in mouse RAW264.7 cells preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
    		[PMID: 33515864]
    RAW264.7 IC50
    9.4 μM
    Compound: DEX
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced IL-6 production after 48 hrs by ELISA
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced IL-6 production after 48 hrs by ELISA
    		[PMID: 30579802]
    REH EC50
    6.7 nM
    Compound: Dexamethasone
    Cytotoxicity against human REH cells overexpressing GR assessed as reduction in cell viability measured after 3 days by resazurin based assay
    Cytotoxicity against human REH cells overexpressing GR assessed as reduction in cell viability measured after 3 days by resazurin based assay
    		[PMID: 34046609]
    RPMI-8226 IC50
    6.5 nM
    Compound: dexamethasone
    Antiproliferative activity against human RPMI8226 cells after 4 days
    Antiproliferative activity against human RPMI8226 cells after 4 days
    		[PMID: 17705362]
    Splenocyte IC50
    0.001 μM
    Compound: Dexa
    Immunomodulatory activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-induced lymphocyte proliferation by measuring [3H]-thymidine uptake after 48 to 72 hrs by scintillation counting analysis
    Immunomodulatory activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-induced lymphocyte proliferation by measuring [3H]-thymidine uptake after 48 to 72 hrs by scintillation counting analysis
    		[PMID: 29523468]
    SW1353 IC50
    1.8 nM
    Compound: DEX
    Transrepression activity at glucocorticoid receptor in human SW1353 cells assessed as repression of IL-1-induced MMP-13 production after 24 hrs by ELISA
    Transrepression activity at glucocorticoid receptor in human SW1353 cells assessed as repression of IL-1-induced MMP-13 production after 24 hrs by ELISA
    		[PMID: 25706100]
    T-cell IC50
    0.005 μM
    Compound: Dexamethasone
    Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells
    Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells
    		[PMID: 11229767]
    T-cell IC50
    1.6 μM
    Compound: Dexamethasone
    Immunosuppressive activity against BALB/C mouse T lymphocytes assessed as reduction in concanavalin A-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method
    Immunosuppressive activity against BALB/C mouse T lymphocytes assessed as reduction in concanavalin A-induced cell proliferation by measuring [3H]-thymidine uptake incubated for 8 hrs by Beta scintillation counting method
    		[PMID: 31961677]
    THP-1 IC50
    0.007 μM
    Compound: dexamethasone
    Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 by ELISA
    Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 by ELISA
    		[PMID: 18625560]
    THP-1 IC50
    0.05 μM
    Compound: dexamethasone
    Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha by ELISA
    Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha by ELISA
    		[PMID: 18625560]
    體外研究
    (In Vitro)

    Dexamethasone (Hexadecadrol) 調(diào)節(jié)多種轉(zhuǎn)錄因子，包括激活蛋白-1、核因子-AT 和核因子-kB，從而激活和抑制參與炎癥反應(yīng)的關(guān)鍵基因[1]。
    Dexamethasone 有效抑制 A549 細(xì)胞釋放粒細(xì)胞-巨噬細(xì)胞集落刺激因子 (GM-CSF)，EC50 為 2.2 nM。Dexamethasone (EC50=36 nM) 誘導(dǎo) β2 受體的轉(zhuǎn)錄被發(fā)現(xiàn)與糖皮質(zhì)激素受體 (GR) DNA 結(jié)合相關(guān)，發(fā)生率高 10-100 倍濃度高于抑制 GM-CSF 釋放。Dexamethasone (IC50=0.5 nM) 抑制 3×κB (NF-κB、IκBα 和 I-κBβ)，這與抑制 GM-CSF 釋放有關(guān)[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    根據(jù) Dexamethasone (DEX) 的血液和多組織濃度-時(shí)間曲線，發(fā)現(xiàn)其組織分布沒有重大性別差異。血細(xì)胞與血漿分配 (0.664) 和血漿游離分?jǐn)?shù) (0.175) 中等，廣泛分布在肝臟中 (Kp=6.76)?？赡苁怯捎?P-糖蛋白介導(dǎo)的外流，與預(yù)期的高滲透性相比，大腦中 DEX 的濃度非常低[5]。
    Dexamethasone (DEX) 可用于動(dòng)物建模，構(gòu)建肌肉萎縮、高血壓和抑郁模型。
    1. 誘導(dǎo)肌肉萎縮[6][7]
    致病原理
    糖皮質(zhì)激素是骨骼肌蛋白降解和上調(diào)泛素蛋白酶體途徑的重要介質(zhì)。Dexamethasone 通過結(jié)合糖皮質(zhì)激素受體誘導(dǎo)脛骨前肌蛋白降解，導(dǎo)致肌肉萎縮。
    具體造模方法：
    Mice: C57BL/6 • male • 6-week-old
    Administration: 5 mg/kg • ip • once daily for 2 weeks
    造模成功指標(biāo)
    分子變化：指標(biāo)增加項(xiàng)--C2C12 泛素連接酶、MuRF1、Atrogin-1、Cbl-b、p-Foxo1、p-Foxo3a。其他--導(dǎo)致 C 肌管蛋白降解。糖皮質(zhì)激素受體易位至細(xì)胞核。
    表型觀測：前肌、腓腸肌、股四頭肌和比目魚肌測重減少。骨骼肌與體重的比值下降。
    同類產(chǎn)品 Betamethasone (HY-13570)
    拮抗產(chǎn)品 Glabridin (HY-N0393)
    2. 誘導(dǎo)高血壓[8][9]
    致病原理
    誘發(fā)高血壓 (HT) 的潛在機(jī)制尚不清楚。
    具體造模方法：
    Rat: Sprague-Dawley • Male • 200-300 g
    Administration: 20?μg • sc • once daily from days 5 to 16 • control rats: saline with 0.1 mL/100 g/day from days 1 to 16 (po) or 0.2 mL/rat/day (sc).
    Dog: 10.1-19.1 kg • average=13.7 kg
    Administration: 0.5 mg/kg • po • once daily for 10 days
    造模成功指標(biāo)
    血流動(dòng)力學(xué)：中樞血流動(dòng)力學(xué)中 MAP、收縮壓、舒張壓、TPR 水平升高?？偼庵茏枇?、血壓、心房鈉尿肽以及對去甲腎上腺素的升壓反應(yīng)在全身和腎臟血流動(dòng)力學(xué)中顯著增加。
    行為觀測：犬表現(xiàn)出明顯的排鈉利尿作用。
    拮抗產(chǎn)品 Saralasin (HY-P0205); Prazosin (HY-B0193)
    3. 誘導(dǎo)抑郁行為[10][11]
    致病原理
    星形膠質(zhì)細(xì)胞是重度抑郁癥 (MD) 的一個(gè)關(guān)鍵特征，糖皮質(zhì)激素表達(dá)減少會(huì)導(dǎo)致星形膠質(zhì)細(xì)胞數(shù)量減少。 長期使用 Dexamethasone 處理會(huì)導(dǎo)致嚙齒類動(dòng)物出現(xiàn)一系列類似抑郁癥的癥狀。
    具體造模方法：
    Rat: Sprague-Dawley • Male • 200-250 g
    Administration: 1 mg/kg • po • once daily every other day for 5 months
    Note
    (1) 制備 3% (w/v) 處理溶液，并通過 0.45 μm 醋酸纖維素過濾器過濾。
    (2) 開始處理前 4 天，老鼠不應(yīng)該接觸除此之外的任何其他水源。
    (3) 第 4 天，將處理液換成水，喂食 3 天，使小鼠暫時(shí)恢復(fù)。第 7 天稱重并進(jìn)行行為實(shí)驗(yàn)。
    Mice: C57BL/6 • Male • 9-10 weeks old • 23-25 g
    Administration: 4 mg/kg • ip • once dailly for 21 days
    造模成功指標(biāo)
    代謝變化：大鼠血清皮質(zhì)醇水平 ↑。
    行為觀測：強(qiáng)迫游泳測試（FST）期間的不動(dòng)時(shí)間 ↑。蔗糖偏好測試中對蔗糖的偏好 ↓。
    拮抗產(chǎn)品 Amitriptyline (HY-B0527)

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    392.46

    Formula

    C22H29FO5
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    地塞米松
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式

    4°C, protect from light

    *In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 100 mg/mL (254.80 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    Ethanol 中的溶解度 : 8.33 mg/mL (21.23 mM; 超聲助溶)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.5480 mL 12.7402 mL 25.4803 mL
    5 mM 0.5096 mL 2.5480 mL 5.0961 mL
    查看完整儲(chǔ)備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C儲(chǔ)存時(shí)，請?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 5% DMSO    95% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (6.37 mM); 澄清溶液

    • 方案 二

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (5.30 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 0.5% CMC-Na/saline water

      Solubility: 18.18 mg/mL (46.32 mM); 懸濁液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
    請輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。

    *In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

    您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.86%

    參考文獻(xiàn)
    Animal Administration
    [3][4]

    Mice[3]
    Female C57Bl/6JBom mice (age 10-12 weeks) are used in all experiments. Dexamethasone is administered as a single injection of 1 or 10 mg/kg. Dexamethasone is dissolved in saline and 400 μL are injected intraperitoneally, either 1 h before or 1 h after LPS exposure. In one experiment, N-acetylcysteine (NAC) (100 and 500 mg/kg) is injected successively every 4?5 h, starting 1 h before challenge (five injections in total). A control group of LPS-exposed animals are injected intraperitoneally with solvent alone (saline). Intratracheal administration is performed by instillation of 100 μL NAC (50, 100 or 500 mg/kg) or Dexamethasone (10 mg/kg) into the lungs of mice.
    Rats[4]
    Male Sprague-Dawley rats are used.Dexamethasone-treated rats are injected intraperitoneally once daily with Dexamethasone (1.5 mg/kg body weight) for 5 days and are allowed to feed ad libitum. The Dexamethasone dose (1.5 mg/kg/day) and the duration of treatment (5 days) are specifically chosen as this treatment induced a reproducible and marked catabolic state. Control rats received no treatment and are fed ad libitum. In order to take into account the decrease in food intake induced by Dexamethasone treatment, a third group of pair-fed rats are used. These rats are provided with the same amount of food as Dexamethasone-injected rats and are treated with a daily isovolumic intraperitoneal injection of NaCl (0.9%) for 5 days. After the final injection of Dexamethasone or NaCl, the animals are fasted overnight prior to being killed by decapitation.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C儲(chǔ)存時(shí)，請?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 2.5480 mL 12.7402 mL 25.4803 mL 63.7008 mL
    5 mM 0.5096 mL 2.5480 mL 5.0961 mL 12.7402 mL
    10 mM 0.2548 mL 1.2740 mL 2.5480 mL 6.3701 mL
    15 mM 0.1699 mL 0.8493 mL 1.6987 mL 4.2467 mL
    20 mM 0.1274 mL 0.6370 mL 1.2740 mL 3.1850 mL
    DMSO 25 mM 0.1019 mL 0.5096 mL 1.0192 mL 2.5480 mL
    30 mM 0.0849 mL 0.4247 mL 0.8493 mL 2.1234 mL
    40 mM 0.0637 mL 0.3185 mL 0.6370 mL 1.5925 mL
    50 mM 0.0510 mL 0.2548 mL 0.5096 mL 1.2740 mL
    60 mM 0.0425 mL 0.2123 mL 0.4247 mL 1.0617 mL
    80 mM 0.0319 mL 0.1593 mL 0.3185 mL 0.7963 mL
    100 mM 0.0255 mL 0.1274 mL 0.2548 mL 0.6370 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Dexamethasone
    目錄號：
    HY-14648
    需求量：